DFO, while effective in animal models, exhibits poor bloodbrain barrier (BBB) permeability, necessitating intranasal or intracerebroventricular delivery to achieve therapeutic concentrations (Guo et al., 2013)
Originally the source for intrinsic factor was virtually unprocessed normal gastric juice obtained from healthy volunteers
Start with tirzepatide monotherapy, titrate to therapeutic dose (12.515mg weekly), allow 1620 weeks to reach plateau, then reassess
But these drugs do expire after a few weeks, and microdosing could increase the risk of inadvertently using them after their expiration date
Atagun M, Atay OC, Balaban OD, Ipekcioglu D, Alpugan B, Yalcin S, Senat A, Karamustafalioglu N, Ilnem MC, Erel O